Raptiva PML Case Brings Another REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants black-box warning, new safety plan for psoriasis drug.
You may also be interested in...
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection
Risk management program couldn't save psoriasis drug. Decision is final, firm says.